Xingjuan Chao Sells 31,415 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 31,415 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $25.03, for a total transaction of $786,317.45. Following the transaction, the chief executive officer directly owned 787,799 shares in the company, valued at approximately $19,718,608.97. The trade was a 3.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, August 18th, Xingjuan Chao sold 2,199 shares of CeriBell stock. The stock was sold at an average price of $25.00, for a total transaction of $54,975.00.
• On Tuesday, July 7th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $19.90, for a total transaction of $776,100.00.
• On Monday, June 8th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The shares were sold at an average price of $18.33, for a total transaction of $714,870.00.

CeriBell Stock Down 2.3%

Shares of CBLL stock traded down $0.58 on Thursday, hitting $24.31. The company’s stock had a trading volume of 262,277 shares, compared to its average volume of 346,888. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79. CeriBell, Inc. has a fifty-two week low of $10.85 and a fifty-two week high of $25.33. The firm’s fifty day moving average price is $19.30 and its 200-day moving average price is $19.16. The stock has a market capitalization of $932.97 million, a price-to-earnings ratio of -13.81 and a beta of 0.81.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Research analysts anticipate that CeriBell, Inc. will post -1.96 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CBLL shares. Canaccord Genuity Group increased their price objective on CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday. Barclays raised CeriBell to a “neutral” rating in a research report on Tuesday. Finally, Weiss Ratings upgraded CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, CeriBell presently has a consensus rating of “Moderate Buy” and an average price target of $22.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. TimesSquare Capital Management LLC acquired a new stake in shares of CeriBell in the second quarter valued at about $15,182,000. Royce & Associates LP acquired a new position in shares of CeriBell during the 4th quarter worth about $11,695,000. KCM Capital Inc boosted its stake in CeriBell by 40.0% during the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after purchasing an additional 400,000 shares during the period. Kopp Family Office LLC bought a new stake in CeriBell during the 2nd quarter valued at approximately $672,000. Finally, Principal Financial Group Inc. grew its holdings in CeriBell by 71.9% in the 1st quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock valued at $425,000 after buying an additional 9,696 shares during the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.